In 2024, Modern Retina covered news from around the globe on clinical trials, technology in retina, trending topics in ...

The researchers conducted a retrospective study to assess serum inflammatory biomarkers in patients with different subtypes ...

The phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis did not meet the primary endpoint of a statistically ...

4DMT announced the publication of preclinical data demonstrating the potential of the Therapeutic Vector Evolution (TVE) platform, intravitreal R100 vector, and the R100-based genetic medicine 4D-150.

Did you miss any of our print issues this year? Don’t worry, they are still available online. In an increasingly digital world, where news moves swiftly and time is crunched, digital reading has ...

A recent study that compared 2 anti-vascular endothelial growth factor drugs for treating diabetic macular edema (DME) found that brolucizumab (Beovu, Novartis) was non-inferior in functional outcomes ...

Finnish researchers, Hanna Heloterä, Anna-Mari Viita, and Juha Laine, reported the results of a study in which they gained a better perspective on registry data and the changing workload in ...

Patients treated with investigational oral therapy gildeuretinol (ALK-001) showed a statistically significant reduction in the GA lesion growth rate.

Curacle plans to finalize its development strategy, including phase 2b and 3 trials, through a Type C meeting with the US FDA in February of 2025. Curacle presented the results of its phase 2a ...

It is noteworthy that patients with mild TBI often report visual issues despite normal results of visual acuity measurements and fundus examinations. The results of a new study 1 suggested that the ...

A research team from Great Britain identified factors, such as mental health issues, lack of diabetic eye screening awareness, and transport difficulties, that interfere with attendance at annual ...